CliffBio
small molecule

VOXZOGO

VOSORITIDE

Loss of exclusivityJuly 2042latest FDA-listed patent expiry
CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameVOXZOGO
Active ingredientVOSORITIDE
Strength0.4MG/VIAL
Dosage formPOWDER
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusRX

Listed patents

PatentExpiresType
12233106July 2042use U-3927
11590204August 2036product
12514906August 2036product
11911446August 2036use U-3927
10646550August 2036product
9907834August 2036product
8198242June 2035substance, product
RE48267May 2030use U-3927

Regulatory exclusivity

CodeExpires
ODE-449October 2030
ODE-387November 2028
NCENovember 2026
NPPOctober 2026

More from Biomarin Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.